Last reviewed · How we verify
Ceftazidime-avibactam + Fosfomycin
Ceftazidime-avibactam inhibits bacterial cell wall synthesis while avibactam protects against beta-lactamase degradation, and fosfomycin disrupts peptidoglycan cross-linking through a different pathway to provide synergistic broad-spectrum coverage.
Ceftazidime-avibactam inhibits bacterial cell wall synthesis while avibactam protects against beta-lactamase degradation, and fosfomycin disrupts peptidoglycan cross-linking through a different pathway to provide synergistic broad-spectrum coverage. Used for Complicated urinary tract infections (cUTI), Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), Complicated intra-abdominal infections (cIAI).
At a glance
| Generic name | Ceftazidime-avibactam + Fosfomycin |
|---|---|
| Sponsor | National University of Singapore |
| Drug class | Beta-lactam/beta-lactamase inhibitor combination + phosphonic acid antibiotic |
| Target | Penicillin-binding proteins (PBPs), beta-lactamases, MurA enzyme |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ceftazidime is a third-generation cephalosporin that binds penicillin-binding proteins and inhibits cell wall synthesis. Avibactam is a beta-lactamase inhibitor that protects ceftazidime from enzymatic degradation by resistant organisms. Fosfomycin is a phosphonic acid antibiotic that inhibits MurA enzyme, blocking early-stage peptidoglycan synthesis. The combination provides enhanced activity against multidrug-resistant gram-negative bacteria including carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
Approved indications
- Complicated urinary tract infections (cUTI)
- Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)
- Complicated intra-abdominal infections (cIAI)
- Multidrug-resistant gram-negative bacterial infections
Common side effects
- Diarrhea
- Nausea
- Headache
- Phlebitis at infusion site
- Elevated liver enzymes
Key clinical trials
- PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE
- A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections (PHASE3)
- Optimising TREATment for Severe Gram-Negative Bacterial Infections (PHASE4)
- Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam Vs. Other Active Antibiotics. a Multicenter Target Trial Emulation.
- Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults (PHASE4)
- PK/PD Analysis of Ceftazidime/Avibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections
- Use of New Antibiotics in Sweden
- Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: